Note 13 - Site-Directed Bone Growth	9 Months Ended
Sep. 30, 2012
Other Assets Disclosure [Text Block]	NOTE M - SITE-DIRECTED BONE GROWTH In September 2011, we sold our non-core asset, the Site Directed Bone Growth program, by assigning seven patent applications to Kieran Murphy, LLC. In addition, we terminated an Exclusive License Agreement and Consulting Agreement with Kieran Murphy, LLC, as well as a License Option Agreement and Research Agreement with Yale University. In exchange for the assignment of the patents and patent applications, we will receive sales royalties in excess of seven percent (7%) and will receive forty percent (40%) of any future licensing revenue and/or forty percent (40%) of all considerations received upon the subsequent sale of the patent portfolio by Kieran Murphy, LLC.

Note 13 - Site-Directed Bone Growth

9 Months Ended

Sep. 30, 2012

NOTE M - SITE-DIRECTED BONE GROWTH

In September 2011, we sold our non-core asset, the Site Directed Bone Growth program, by assigning seven patent applications to Kieran Murphy, LLC. In addition, we terminated an Exclusive License Agreement and Consulting Agreement with Kieran Murphy, LLC, as well as a License Option Agreement and Research Agreement with Yale University. In exchange for the assignment of the patents and patent applications, we will receive sales royalties in excess of seven percent (7%) and will receive forty percent (40%) of any future licensing revenue and/or forty percent (40%) of all considerations received upon the subsequent sale of the patent portfolio by Kieran Murphy, LLC.